다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

LTRN

Lantern Pharma (LTRN)

Lantern Pharma Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:LTRN

1 2 3 4 5 6 7 8 9 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/12/09	22:15	Business Wire	Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients	NASDAQ:LTRN	Lantern Pharma Inc
2024/12/03	22:00	Business Wire	Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)	NASDAQ:LTRN	Lantern Pharma Inc
2024/11/26	22:45	Business Wire	Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality	NASDAQ:LTRN	Lantern Pharma Inc
2024/11/19	22:00	Business Wire	Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients	NASDAQ:LTRN	Lantern Pharma Inc
2024/11/08	06:07	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:LTRN	Lantern Pharma Inc
2024/11/08	06:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LTRN	Lantern Pharma Inc
2024/11/08	06:05	Business Wire	Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates	NASDAQ:LTRN	Lantern Pharma Inc
2024/11/05	22:00	Business Wire	Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board	NASDAQ:LTRN	Lantern Pharma Inc
2024/10/31	21:00	Business Wire	Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET	NASDAQ:LTRN	Lantern Pharma Inc
2024/10/23	21:45	Business Wire	Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024	NASDAQ:LTRN	Lantern Pharma Inc
2024/10/21	21:00	Business Wire	Lantern Pharma to Host & Participate in Two Public Webinars During October	NASDAQ:LTRN	Lantern Pharma Inc
2024/10/15	22:07	Business Wire	Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA	NASDAQ:LTRN	Lantern Pharma Inc
2024/09/23	21:00	Business Wire	Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers	NASDAQ:LTRN	Lantern Pharma Inc
2024/08/09	05:07	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:LTRN	Lantern Pharma Inc
2024/08/09	05:01	Business Wire	Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates	NASDAQ:LTRN	Lantern Pharma Inc
2024/08/07	22:31	Business Wire	Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024	NASDAQ:LTRN	Lantern Pharma Inc
2024/08/05	21:00	Business Wire	Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort	NASDAQ:LTRN	Lantern Pharma Inc
2024/08/01	21:00	Business Wire	Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET	NASDAQ:LTRN	Lantern Pharma Inc
2024/07/18	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LTRN	Lantern Pharma Inc
2024/07/18	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LTRN	Lantern Pharma Inc
2024/07/18	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LTRN	Lantern Pharma Inc
2024/07/18	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LTRN	Lantern Pharma Inc
2024/07/10	21:30	Business Wire	Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184	NASDAQ:LTRN	Lantern Pharma Inc
2024/06/18	05:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LTRN	Lantern Pharma Inc
2024/06/12	20:30	Business Wire	Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284	NASDAQ:LTRN	Lantern Pharma Inc
2024/06/11	13:16	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/25	05:09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/25	05:08	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/25	05:06	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/13	14:30	Business Wire	Oregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur...	NASDAQ:LTRN	Lantern Pharma Inc

검색 관련기사 보기:NASDAQ:LTRN

1 2 3 4 5 6 7 8 9 다음 >>

Verizon Communications

US Dollar vs Yen

US Dollar vs Euro

BNP Paribas (QX)

Financial Select Sector

Deutsche Telekom (QX)

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관